Progress of enhancer of zeste homolog 2 in hematological tumors / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 442-445, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-989005
ABSTRACT
The enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase, which is widely studied in histone methylation modification. It can promote epigenetic gene silencing and mediate the occurrence of tumors through a variety of regulatory mechanisms. The gain-of-function and loss-of-function mutations of EZH2 have been confirmed in many cancers. At present, with the extensive attention paid to the regulatory role of EZH2 in epigenetic mechanism, the exact way in which EZH2 imbalance affects the pathogenesis of hematologic malignancies remains to be clarified. This article reviews the pathogenetic role of EZH2 in hematological tumors, and hope to find new targets for the prevention and treatment of hematological tumors.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS